C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD

Tools

Item Type:	Article
Title:	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD
Creators Name:	Pache, F., Ringelstein, M., Aktas, O., Kleiter, I., Jarius, S., Siebert, N., Bellmann-Strobl, J., Paul, F. and Ruprecht, K.
Abstract:	While complement-dependent cytotoxicity (CDC) is a known effector mechanism in aquaporin-4-immunoglobulin (Ig)G-positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD), the role of CDC in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear. We determined complement C3 and C4 plasma concentrations in patients with clinically stable AQP4-IgG+ NMOSD (n = 16), MOGAD (n = 15), early multiple sclerosis (MS, n = 19) and in healthy controls (HC, n = 18). C4 was lower in AQP4-IgG+ NMOSD than in MOGAD, MS and HC (p < 0.05, pairwise comparisons). C3 was lower in AQP4-IgG+ NMOSD than in MS (p = 0.034). These findings suggest subtle complement consumption in clinically stable AQP4-IgG+ NMOSD, but not in MOGAD.
Keywords:	Antibodies, Aquaporin-4, C3, C4, Complement, Myelin Oligodendrocyte Glycoprotein, Neuromyelitis Optica Spectrum Disorder
Source:	Journal of Neuroimmunology
ISSN:	0165-5728
Publisher:	Elsevier
Volume:	360
Page Range:	577699
Date:	15 November 2021
Official Publication:	https://doi.org/10.1016/j.jneuroim.2021.577699
PubMed:	View item in PubMed

Repository Staff Only: item control page